Article
Biology
Marius-Alexandru Beleaua, Ioan Jung, Cornelia Braicu, Doina Milutin, Simona Gurzu
Summary: The study investigated the diagnostic and prognostic utility of conventional pan-melanoma cocktail members in malignant melanoma, in combination with SOX10 and SOX11 immunohistochemical expression. SOX11 positivity was directly correlated with clinicopathological factors, while the conventional pan-melanoma cocktail successfully differentiated benign nevi from melanomas.
Article
Immunology
Chiara M. Biatta, Michele Paudice, Marco Greppi, Veronica Parrella, Alessia Parodi, Giuseppa De Luca, Gianna Maria Cerruti, Serafina Mammoliti, Cinzia Caroti, Paola Menichini, Gilberto Fronza, Silvia Pesce, Emanuela Marcenaro, Valerio G. Vellone
Summary: This study investigated the concordance between immunohistochemical p53 staining and TP53 mutations in HGSOC, and explored prognostic differences between p53 overexpression and null expression groups. The results showed that all cases with a null immunohistochemical p53 expression had TP53 mutations, while 16 out of 18 cases with p53 overexpression had TP53 missense mutations. Follow-up data revealed a significant reduction in overall survival for the p53 null group. Therefore, immunohistochemical assay can serve as a reliable surrogate for TP53 mutations, and HGSOC with p53 null mutations are associated with a more aggressive subtype.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yasemin C. Cole, Yu-Zhi Zhang, Beatrice Gallo, Adam P. Januszewski, Anca Nastase, David J. Essex, Caroline M. H. Thaung, Victoria M. L. Cohen, Mandeep S. Sagoo, Anne M. Bowcock
Summary: A study on 100 uveal melanomas from the UK revealed that loss of nuclear BAP1 (nBAP1) predicts shorter overall survival. Tumors with BAP1 loss of function mutations frequently exhibited heterogeneous BAP1 staining, and tumors with >= 25% loss of nBAP1 were a more reliable prognostic indicator than chromosome 3 loss (LOH3) or chromosome 8q gain. Majority of BAP1 mutations result in loss of nBAP1 and aberrant expression of cBAP1.
Editorial Material
Oncology
Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long
Summary: Neoadjuvant immunotherapy, especially in melanoma, is showing promising safety and activity. It may soon become a standard-of-care in drug development.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
J. Jha, M. K. Singh, L. Singh, N. Pushker, N. Lomi, R. Meel, K. Chosdol, S. Sen, S. Bakhshi, S. Kashyap
Summary: This study investigated the expression of TYRP1 and HIF-1 alpha in uveal melanoma samples and found that both were associated with high pigmentation and BAP1 loss, and correlated with poor prognosis. High immunoexpression of TYRP1 and HIF-1 alpha may serve as potential biomarkers in the development of targeted therapy for uveal melanoma, with further research on melanogenesis markers needed for a better understanding of the field.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Mingxiao Li, Gehong Dong, Weiwei Zhang, Xiaohui Ren, Haihui Jiang, Chuanwei Yang, Xuzhe Zhao, Qinghui Zhu, Ming Li, Hongyan Chen, Kefu Yu, Yong Cui, Lin Song
Summary: Pyrosequencing is the gold standard for determining MGMT promoter status, but binary interpretation of results may overlook the gray zone. A study on 312 primary glioblastoma patients found a gray zone subgroup with intermediate prognosis. Immunohistochemistry scores were more effective in predicting prognosis for gray zone patients, and combining PSQ and IHC significantly improved the predictive ability for clinical outcomes.
Article
Oncology
M. Mandala, P. Rutkowski, F. Galli, R. Patuzzo, V. De Giorgi, E. Rulli, A. Gianatti, B. Valeri, B. Merelli, A. Szumera-Cieckiewicz, D. Massi, A. Maurichi, P. Teterycz, M. Santinami
Summary: Acral lentiginous melanoma (ALM) is associated with worse long-term disease-free survival (DFS), and its inclusion as an independent prognostic factor in the new AJCC classification could have important clinical implications.
Article
Oncology
M. Mandala, P. Rutkowski, F. Galli, R. Patuzzo, V. De Giorgi, E. Rulli, A. Gianatti, B. Valeri, B. Merelli, A. Szumera-Cieckiewicz, D. Massi, A. Maurichi, P. Teterycz, M. Santinami
Summary: Acral lentiginous melanoma (ALM) has a negative impact on disease-free survival (DFS) in patients. These findings have important clinical implications for patient stratification in future clinical trials and the AJCC classification.
Article
Biochemistry & Molecular Biology
Jonathan Schupp, Arne Christians, Niklas Zimmer, Lukas Gleue, Helmut Jonuleit, Mark Helm, Andrea Tuettenberg
Summary: The presence and interaction of immune cells in the tumor microenvironment have a significant impact on disease progression and treatment response. Spatial analyses are crucial in the complex interplay between neoplastic and immune cells, aiming to develop new therapeutic strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Alexander C. Huang, Michael T. Tetzlaff, Bart A. van de Wiel, Serigne Lo, Ahmad A. Tarhini, Elizabeth M. Burton, Thomas E. Pennington, Robyn P. M. Saw, Xiaowei Xu, Giorgos C. Karakousis, Paolo A. Ascierto, Andrew J. Spillane, Alexander C. J. van Akkooi, Michael A. Davies, Tara C. Mitchell, Hussein A. Tawbi, Richard A. Scolyer, Jennifer A. Wargo, Christian U. Blank, Georgina V. Long
Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.
Review
Oncology
Malgorzata Gajdzis, Radoslaw Kaczmarek, Pawel Gajdzis
Summary: Uveal melanoma is the most common primary intraocular neoplasm in adults with a high rate of distant metastases and no effective treatment in the advanced stage. The search for new prognostic factors is crucial for understanding the disease's biology, monitoring patients effectively, and identifying potential therapeutic targets. Numerous studies have demonstrated the complexity of uveal melanoma biology and the potential for individualized treatment approaches based on protein expression patterns.
Article
Oncology
Sophie Engelhardt, Felix Behling, Rudi Beschorner, Franziska Eckert, Patricia Kohlhof, Marcos Tatagiba, Ghazaleh Tabatabai, Martin U. Schuhmann, Martin Ebinger, Jens Schittenhelm
Summary: FGFR1 hotspot mutations are the fifth most prevailing alteration in LGG/MNGT. Performing FGFR1 sequencing analysis in driver-unknown low-grade brain tumors could yield up to 12% FGFR1 N546/K656 mutant cases.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Karolina Rowinska, Piotr Baszuk, Emilia Rogoza-Janiszewska, Jakub Deptula, Wojciech Marciniak, Roza Derkacz, Marcin Lener, Cezary Cybulski, Magdalena Kiedrowicz, Magdalena Boer, Mariola Marchlewicz, Tadeusz Debniak, Jan Lubinski
Summary: Low serum iron concentration is associated with increased mortality in patients with malignant melanoma. Patients with low iron levels have significantly lower survival rates.
Article
Oncology
Jordan W. Conway, Robert Rawson, Serigne Lo, Tasnia Ahmed, Ismael A. Vergara, Tuba N. Gide, Grace Heloise Attrill, Matteo S. Carlino, Robyn P. M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Brindha Shivalingam, Alexander Maxwell Menzies, James S. Wilmott, Georgina Long, Richard A. Scolyer, Ines Pires da Silva
Summary: This study aimed to compare the tumor immune microenvironment of melanoma metastases in different anatomical sites. The results showed that liver and brain metastases had lower immune infiltrate, which may contribute to poorer prognosis and reduced response to immunotherapy. Additionally, increased TIM-3 expression in liver metastases suggests a potential therapeutic opportunity for improving patient outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Emilia Rogoza-Janiszewska, Karolina Malinska, Piotr Baszuk, Wojciech Marciniak, Roza Derkacz, Marcin Lener, Anna Jakubowska, Cezary Cybulski, Tomasz Huzarski, Bartlomiej Masojc, Jacek Gronwald, Helena Rudnicka, Andrzej Kram, Magdalena Kiedrowicz, Magdalena Boer, Tadeusz Debniak, Jan Lubinski
Summary: The study found that patients with low serum selenium levels had a higher mortality rate in the 10 years following melanoma diagnosis compared to patients with high selenium levels. Future studies in regions with low soil selenium levels are needed to confirm these findings.
Letter
Oncology
Michael Constantin Kirchberger, Bastian Schilling, Sebastian Haferkamp, Anja Bosserhoff, Gerold Schuler, Lucie Heinzerling
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2018)
Article
Oncology
Lisa Walter, Lucie Heinzerling
ANTICANCER RESEARCH
(2018)
Article
Biochemistry & Molecular Biology
Florian S. Dreyer, Martina Cantone, Martin Eberhardt, Tanushree Jaitly, Lisa Walter, Juergen Wittmann, Shailendra K. Gupta, Faiz M. Khan, Olaf Wolkenhauer, Brigitte M. Puetzer, Hans-Martin Jack, Lucie Heinzerling, Julio Vera
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2018)
Article
Oncology
Markus Hecht, Friedegund Meier, Lisa Zimmer, Bulent Polat, Carmen Loquai, Carsten Weishaupt, Andrea Forschner, Ralf Gutzmer, Jochen S. Utikal, Simone M. Goldinger, Michael Geier, Jessica C. Hassel, Panagiotis Balermpas, Felix Kiecker, Ricarda Rauschenberg, Ursula Dietrich, Patrick Clemens, Carola Berking, Gerhard Grabenbauer, Dirk Schadendorf, Stephan Grabbe, Gerold Schuler, Rainer Fietkau, Luitpold V. Distel, Lucie Heinzerling
BRITISH JOURNAL OF CANCER
(2018)
Article
Dermatology
A. Moreira, M. C. Kirchberger, F. Toussaint, M. Erdmann, G. Schuler, L. Heinzerling
BRITISH JOURNAL OF DERMATOLOGY
(2018)
Article
Oncology
Katharina C. Kaehler, Thomas K. Eigentler, Anja Gesierich, Lucie Heinzerling, Carmen Loquai, Friedegund Meier, Frank Meiss, Claudia Pfoehler, Max Schlaak, Patrick Terheyden, Kai M. Thoms, Mirjana Ziemer, Lisa Zimmer, Ralf Gutzmer
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2018)
Article
Oncology
Michael Constantin Kirchberger, Selma Ugurel, Johanna Mangana, Markus Valentin Heppt, Thomas Kurt Eigentler, Carola Berking, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie Heinzerling
EUROPEAN JOURNAL OF CANCER
(2018)
Article
Biochemistry & Molecular Biology
Jan Doerrie, Lek Babalija, Stefanie Hoyer, Kerstin F. Gerer, Gerold Schuler, Lucie Heinzerling, Niels Schaft
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Oncology
Alvaro Moreira, Stefanie Gross, Michael Constantin Kirchberger, Michael Erdmann, Gerold Schuler, Lucie Heinzerling
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Oncology
Alvaro Moreira, Carmen Loquai, Claudia Pfoefer, Katharina C. Kaehler, Samuel Knauss, Markus V. Heppt, Ralf Gutzmer, Florentia Dimitriou, Friedegund Meier, Heidrun Mitzel-Rink, Gerold Schuler, Patrick Terheyden, Kai-Martin Thoms, Matthias Tuerk, Reinhard Dummer, Lisa Zimmer, Rolf Schroeder, Lucie Heinzerling
EUROPEAN JOURNAL OF CANCER
(2019)
Article
Dermatology
Marie K. Priebe, Nadin Dewert, Katharina Amschler, Luise Erpenbeck, Lucie Heinzerling, Michael P. Schoen, Cornelia S. Seitz, Verena N. Lorenz
EXPERIMENTAL DERMATOLOGY
(2019)
Article
Microbiology
Florian Full, Michiel van Gent, Konstantin M. J. Sparrer, Cindy Chiang, Matthew A. Zurenski, Myriam Scherer, Norbert H. Brockmeyer, Lucie Heinzerling, Michael Sturzl, Klaus Korn, Thomas Stamminger, Armin Ensser, Michaela U. Gack
NATURE MICROBIOLOGY
(2019)
Article
Oncology
Annika Krueckel, Alvaro Moreira, Waltraud Froehlich, Gerold Schuler, Lucie Heinzerling
Article
Oncology
Magid Awadalla, Doll Lauren Alexandra Golden, Syed S. Mahmood, Raza M. Alvi, Nathaniel D. Mercaldo, Malek Z. O. Hassan, Dahlia Banerji, Adam Rokicki, Connor Mulligan, Sean P. T. Murphy, Maeve Jones-O'Connor, Justine V. Cohen, Lucie M. Heinzerling, Merna Armanious, Ryan J. Sullivan, Rongras Damrongwatanasuk, Carol L. Chen, Dipti Gupta, Michael C. Kirchberger, Javid J. Moslehi, Sachin P. Shah, Sarju Ganatra, Paaladinesh Thavendiranathan, Muhammad A. Rizvi, Gagan Sahni, Alexander R. Lyon, Carlo G. Tocchetti, Valentina Mercurio, Franck Thuny, Stephane Ederhy, Michael Mahmoudi, Donald P. Lawrence, John D. Groarke, Anju Nohria, Michael G. Fradley, Kerry L. Reynolds, Tomas G. Neilan
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2019)
Article
Oncology
Titus J. Brinker, Achim Hekler, Alexander H. Enk, Joachim Klode, Axel Hauschild, Carola Berking, Bastian Schilling, Sebastian Haferkamp, Dirk Schadendorf, Stefan Froehling, Jochen S. Utikal, Christof von Kalle, Wiebke Ludwig-Peitsch, Judith Sirokay, Lucie Heinzerling, Magarete Albrecht, Katharina Baratella, Lena Bischof, Eleftheria Chorti, Anna Dith, Christina Drusio, Nina Giese, Emmanouil Gratsias, Klaus Griewank, Sandra Hallasch, Zdenka Hanhart, Saskia Herz, Katja Hohaus, Philipp Jansen, Finja Jockenhoefer, Theodora Kanaki, Sarah Knispel, Katja Leonhard, Anna Martaki, Liliana Matei, Johanna Matull, Alexandra Olischewski, Maximilian Petri, Jan-Malte Placke, Simon Raub, Katrin Salva, Swantje Schlott, Elsa Sody, Nadine Steingrube, Ingo Stoffels, Selma Ugurel, Wiebke Sondermann, Anne Zaremba, Christoffer Gebhardt, Nina Booken, Maria Christolouka, Kristina Buder-Bakhaya, Therezia Bokor-Billmann, Alexander Enk, Patrick Gholam, Holger Haenssle, Martin Salzmann, Sarah Schaefer, Knut Schaekel, Timo Schank, Ann-Sophie Bohne, Sophia Deffaa, Katharina Drerup, Friederike Egberts, Anna-Sophie Erkens, Benjamin Ewald, Sandra Falkvoll, Sascha Gerdes, Viola Harde, Axel Hauschild, Marion Jost, Katja Kosova, Laetitia Messinger, Malte Metzner, Kirsten Morrison, Rogina Motamedi, Anja Pinczker, Anne Rosenthal, Natalie Scheller, Thomas Schwarz, Dora Stoelzl, Federieke Thielking, Elena Tomaschewski, Ulrike Wehkamp, Michael Weichenthal, Oliver Wiedow, Claudia Maria Baer, Sophia Bender-Saebelkampf, Marc Horbruegger, Ante Karoglan, Luise Kraas, Joerg Faulhaber, Cyrill Geraud, Ze Guo, Philipp Koch, Miriam Linke, Nolwenn Maurier, Verena Mueller, Benjamin Thomas, Jochen Sven Utikal, Ali Saeed M. Alamri, Andrea Baczako, Carola Berking, Matthias Betke, Carolin Haas, Daniela Hartmann, Markus V. Heppt, Katharina Kilian, Sebastian Krammer, Natalie Lidia Lapczynski, Sebastian Mastnik, Suzan Nasifoglu, Cristel Ruini, Elke Sattler, Max Schlaak, Hans Wolff, Birgit Achatz, Astrid Bergbreiter, Konstantin Drexler, Monika Ettinger, Sebastian Haferkamp, Anna Halupczok, Marie Hegemann, Verena Dinauer, Maria Maagk, Marion Mickler, Biance Philipp, Anna Wilm, Constanze Wittmann, Anja Gesierich, Valerie Glutsch, Katrin Kahlert, Andreas Kerstan, Bastian Schilling, Philipp Schruefer
EUROPEAN JOURNAL OF CANCER
(2019)